Longitude Capital Amends Vera Therapeutics Stake
Ticker: VERA · Form: SC 13D/A · Filed: Feb 5, 2024 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | SC 13D/A |
| Filed Date | Feb 5, 2024 |
| Risk Level | medium |
| Pages | 10 |
| Reading Time | 11 min |
| Key Dollar Amounts | $0.001, $31.00 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-ownership, amendment, institutional-investor
TL;DR
**Longitude Capital updated its Vera Therapeutics stake, watch for potential market reaction.**
AI Summary
Longitude Capital Partners IV, LLC, along with its affiliates, filed an amended Schedule 13D on February 5, 2024, indicating a change in their beneficial ownership of Vera Therapeutics, Inc. Class A Common Stock. The filing, triggered by an event on February 1, 2024, updates their stake in the pharmaceutical company. This matters to investors because significant changes in ownership by large institutional investors like Longitude Capital can signal shifts in confidence or strategic intent regarding Vera Therapeutics' future prospects.
Why It Matters
Changes in major institutional holdings can influence stock perception and liquidity, potentially signaling a vote of confidence or concern in Vera Therapeutics' drug development pipeline.
Risk Assessment
Risk Level: medium — While not inherently negative, a change in a major investor's position introduces uncertainty about their long-term commitment and could impact stock stability.
Analyst Insight
Investors should monitor subsequent filings from Longitude Capital and Vera Therapeutics for more details on the nature of this ownership change, as it could precede further buying, selling, or strategic involvement.
Key Players & Entities
- Longitude Capital Partners IV, LLC (company) — the filing entity and a major investor in Vera Therapeutics, Inc.
- Vera Therapeutics, Inc. (company) — the subject company whose Class A Common Stock is being reported
- Patrick G. Enright (person) — Managing Member of Longitude Capital Partners IV, LLC and authorized contact for the filing
- February 1, 2024 (date) — the date of the event requiring the filing of this amendment
- February 5, 2024 (date) — the filing date of the SC 13D/A
- Class A Common Stock, $0.001 par value per share (other) — the specific class of securities held by the reporting person
FAQ
Who is the primary reporting entity for this SC 13D/A filing?
The primary reporting entity for this SC 13D/A filing is Longitude Capital Partners IV, LLC.
What is the subject company whose shares are being reported in this filing?
The subject company is Vera Therapeutics, Inc., a pharmaceutical preparations company.
What specific type of security is the subject of this filing?
The specific type of security is Class A Common Stock, with a $0.001 par value per share, of Vera Therapeutics, Inc.
When did the event occur that triggered the requirement for this amendment?
The event that triggered the requirement for this amendment occurred on February 1, 2024.
Who is listed as the person authorized to receive notices and communications for the filing entity?
Patrick G. Enright, Managing Member of Longitude Capital Partners IV, LLC, is listed as the person authorized to receive notices and communications.
Filing Stats: 2,865 words · 11 min read · ~10 pages · Grade level 12.8 · Accepted 2024-02-05 16:45:57
Key Financial Figures
- $0.001 — Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class o
- $31.00 — ommon Stock at a price to the public of $31.00 per share (the February 2024 Follow-on
Filing Documents
- d672032dsc13da.htm (SC 13D/A) — 113KB
- 0001193125-24-024125.txt ( ) — 115KB
of the Original Schedule 13D is hereby amended to add the following language
Item 6 of the Original Schedule 13D is hereby amended to add the following language: On February 1, 2024, the Issuer completed a public offering pursuant to which the Issuer issued and sold 8,064,517 shares of Class A Common Stock at a price to the public of $31.00 per share (the February 2024 Follow-on Offering ). In connection with the Follow-on Offering, LVPIV has entered into a lock-up agreement, pursuant to which LVPIV agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Issuers securities held by LVPIV for 45 days following the date of the final prospectus for the February 2024 Follow-on Offering. The terms and provisions of such lock-up agreement are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 8 to this Statement and is incorporated herein by reference. Item7. Material to be Filed as Exhibits. Exhibit 8: Form of Lock-Up Agreement for certain directors, officers and other stockholders of the Issuer (included as Exhibit A to the form of Underwriting Agreement filed as Exhibit 1.1 to the Issuers Current Report on Form 8-K as filed with the Commission on January 30, 2024). SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 5, 2024 LONGITUDE VENTURE PARTNERS IV, L.P. By: LONGITUDE CAPITAL PARTNERS IV, LLC Its: General Partner By: /s/ Cristiana Blauth Oliveira Cristiana Blauth Oliveira, Authorized Signatory LONGITUDE CAPITAL PARTNERS IV, LLC By: /s/ Cristiana Blauth Oliveira Cristiana Blauth Oliveira, Authorized Signatory LONGITUDE PRIME FUND, L.P. By: LONGITUDE PRIME PARTNERS, LLC Its: General Partner By: /s/ Cristiana Blauth Oliveira Cristiana Blauth Oliveira, Authorized Signatory LONGI